Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?

D. Escors, T. Liechtenstein, N. Perez-Janices, J. Schwarze, Inès Dufait, Cleo Goyvaerts, A. Lanna, F. Arce, I. Blanco-Luquin, G. Kochan, D. Guerrero-Setas, Karine Breckpot

Research output: Contribution to journalScientific review

22 Citations (Scopus)

Abstract

Since dendritic cells operate as professional antigen-presenting cells (APCs) and hence are capable of jumpstarting the immune system, they have been exploited to develop a variety of immunotherapeutic regimens against cancer. In the few past years, myeloid-derived suppressor cells (MDSCs) have been shown to mediate robust immunosuppressive functions, thereby inhibiting tumor-targeting immune responses. Thus, we propose that the immunomodulatory activity of MDSCs should be carefully considered for the development of efficient anticancer immunotherapies.
Original languageEnglish
Article numbere26148
Number of pages9
JournalOncoImmunology
Volume2
Issue number10
DOIs
Publication statusPublished - 1 Oct 2013

Keywords

  • T cell
  • cancer
  • immunotherapy
  • dendritic cell
  • myeloid
  • suppressor cell

Fingerprint

Dive into the research topics of 'Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?'. Together they form a unique fingerprint.

Cite this